Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Exposure science

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Exposure science. Displaying page 5 of 5.
    « Previous 1  2  3  4  5 
    EudraCT Number: 2005-000346-36 Sponsor Protocol Number: BPLG-004 Start Date*: Information not available in EudraCT
    Sponsor Name:BioPartners GmbH [...]
    1. BioPartners GmbH
    2. LG Life Science Ltd.
    Full Title: A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Dai...
    Medical condition: pre-pubertal drug naïve growth-deficient children with insufficient endogenous growth hormone secretion
    Disease: Version SOC Term Classification Code Term Level
    10056438 LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) FI (Prematurely Ended) SE (Prematurely Ended) SK (Completed) HU (Completed) CZ (Prematurely Ended) IT (Completed) DE (Completed) LT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002277-11 Sponsor Protocol Number: 20120123 Start Date*: 2015-06-23
    Sponsor Name:Amgen Inc
    Full Title: Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Choleste...
    Medical condition: Heterozygous familial hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) Outside EU/EEA GR (Completed) NL (Completed) GB (Completed) AT (Completed) HU (Completed) SI (Completed) PT (Completed) PL (Completed) NO (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-002033-21 Sponsor Protocol Number: NKV102551 Start Date*: 2006-09-11
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonis...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Highly Emetogenic Chemotherapy (HEC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008448 Chemotherapy induced emesis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) IE (Completed) GR (Completed) BE (Completed) CZ (Completed) SK (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004293-33 Sponsor Protocol Number: RPC01-3202 Start Date*: 2018-03-06
    Sponsor Name:Celgene International II Sàrl
    Full Title: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) LT (Completed) DE (Completed) FR (Completed) SI (Completed) AT (Completed) BG (Completed) GR (Completed) ES (Completed) SE (Completed) NL (Completed) PL (Completed) PT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-003772-21 Sponsor Protocol Number: MPP111782 Start Date*: 2009-05-06
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A TWO-PART, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY TO INVESTIGATE THE USE OF MEPOLIZUMAB (SB-240563) IN REDUCING THE NEED FOR SURGERY IN SUBJECTS WITH SEVERE BILATERAL NAS...
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028756 Nasal polyps LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004294-14 Sponsor Protocol Number: RPC01-3203 Start Date*: 2018-03-06
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned) LT (Completed) FR (Trial now transitioned) SI (Completed) AT (Completed) BG (Trial now transitioned) DE (Trial now transitioned) GR (Completed) ES (Ongoing) SE (Prematurely Ended) NL (Completed) NO (Completed) PL (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Completed) DK (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004292-31 Sponsor Protocol Number: RPC01-3201 Start Date*: 2018-05-21
    Sponsor Name:Celgene International II Sàrl
    Full Title: Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) DE (Completed) BG (Prematurely Ended) ES (Ongoing) NO (Completed) BE (Completed) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended) GB (GB - no longer in EU/EEA) HR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005491-41 Sponsor Protocol Number: B1931022 Start Date*: 2012-06-13
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia...
    Medical condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) ES (Completed) GB (Completed) DE (Completed) FI (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000021-27 Sponsor Protocol Number: ZN-c3-003 Start Date*: Information not available in EudraCT
    Sponsor Name:K-Group Beta
    Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma
    Medical condition: Relapsed or Refractory Osteosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10039498 Bone sarcomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000660-17 Sponsor Protocol Number: TPL108392 Start Date*: 2009-07-29
    Sponsor Name:GlaxoSmithKline
    Full Title: TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl...
    Medical condition: Thrombocytopenic subjects with hepatitis C viral infection (HCV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002025-19 Sponsor Protocol Number: RPC01-2201 Start Date*: 2015-12-30
    Sponsor Name:Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
    Full Title: A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Act...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10058815 Crohn's disease acute episode LLT
    20.0 100000004856 10011402 Crohn's disease (colon) LLT
    20.0 100000004856 10011403 Crohn's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 21:49:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA